No Data
No Data
No Data
No Data
No Data
Minerva Neurosciences Price Target Cut to $7.00/Share From $11.00 by HC Wainwright & Co.
Minerva Neurosciences Price Target Cut to $7.00/Share From $11.00 by HC Wainwright & Co.
Dow JonesMay 3 01:42
HC Wainwright & Co. Maintains Neutral on Minerva Neurosciences, Lowers Price Target to $7
HC Wainwright & Co. analyst Douglas Tsao maintains Minerva Neurosciences with a Neutral and lowers the price target from $11 to $7.
Analyst UpgradesMay 3 01:31
Minerva Neurosciences Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/02/2024 194.12% HC Wainwright & Co. $11 → $7 Maintains Neutral 02/27/2024 362.18% HC Wainwright & Co. →
BenzingaMay 3 01:30
Minerva Neurosciences (NERV.US): The 2024 Q1 financial report achieved revenue of $0, with a previous value of $0; earnings per share of -1.13 dollars, previous value of -1.31 dollars, expected value of -1.20 dollars.
Minerva Neurosciences (NERV.US): The 2024 Q1 financial report achieved revenue of $0, with a previous value of $0; earnings per share of -1.13 dollars, previous value of -1.31 dollars, expected value of -1.20 dollars.
Zhitong FinanceMay 1 21:11
Minerva Neurosciences Q1 2024 GAAP EPS $(1.13) Beats $(1.20) Estimate; Cash, Cash Equivalents And Restricted Cash Of $34.9M
Minerva Neurosciences (NASDAQ:NERV) reported quarterly losses of $(1.13) per share which beat the analyst consensus estimate of $(1.20) by 5.83 percent. This is a 13.74 percent increase over losses of
BenzingaMay 1 20:16
Minerva Neurosciences in Discussions With FDA Over Issues, Clinical Deficiencies Related to Roluperidone >NERV
Minerva Neurosciences in Discussions With FDA Over Issues, Clinical Deficiencies Related to Roluperidone >NERV
Dow JonesMay 1 19:32
No Data
No Data